EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Navigating the Nomenclature of Liver Steatosis: Transitioning from NAFLD to MAFLD and MASLD - Understanding Affinities and Differences

Apichat Kaewdech, Pimsiri Sripongpun

Siriraj Medical Journal · 01.04.2024 · 76 (4) · 234-243

DOI: 10.33192/smj.v76i4.267556 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Siriraj Medical Journal, online erschienen am 01.04.2024. Verfasst von Apichat Kaewdech und 1 weiteren Autor:innen. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The escalating prevalence of non-alcoholic fatty liver disease (NAFLD) represents a significant challenge to public health, with an increasing impact observed across various demographics. This review delivers a comprehensive evaluation of the evolving terminology in steatotic liver disease (SLD), documenting the transition from NAFLD to metabolic dysfunction-associated fatty liver disease (MAFLD), and progressing to the latest terms, metabolic dysfunction-associated fatty liver disease (MASLD) and MASLD with increased alcohol intake (MetALD). We conducted a comprehensive review of literature discussing the benefits and drawbacks of these nomenclatural changes. Clinical evidence supporting MASLD and MetALD, including the implications of alcohol consumption thresholds on disease classification and outcomes, was analyzed. The “MAFLD” and “MASLD” labels align with the pathophysiology of metabolic diseases, afford a positive disease connotation, and facilitate the identification of more severe diseases, such as significant fibrosis or advanced liver disease. However, the MAFLD criteria may underdiagnose lean, non-overweight, or non-obese individuals with MAFLD. The review underscores the understanding of liver diseases linked to metabolic dysfunction and alcohol use. The shift in terminology marks progress towards a clinical diagnosis that reflects underlying pathophysiology. However, additional studies are necessary to assess the longterm effects of these changes and their efficacy in enhancing patient care and health outcomes.

Zitieren

APA

Kaewdech, A., & Sripongpun, P. (2024). Navigating the Nomenclature of Liver Steatosis: Transitioning from NAFLD to MAFLD and MASLD - Understanding Affinities and Differences. Siriraj Medical Journal, 76(4), 234-243. https://doi.org/10.33192/smj.v76i4.267556

Vancouver

Kaewdech A, Sripongpun P. Navigating the Nomenclature of Liver Steatosis: Transitioning from NAFLD to MAFLD and MASLD - Understanding Affinities and Differences. Siriraj Medical Journal. 2024;76(4):234-243. doi:10.33192/smj.v76i4.267556

BibTeX
@article{Kaewdech2024,
  author = {Kaewdech, Apichat and Sripongpun, Pimsiri},
  title = {Navigating the Nomenclature of Liver Steatosis: Transitioning from NAFLD to MAFLD and MASLD - Understanding Affinities and Differences},
  journal = {Siriraj Medical Journal},
  year = {2024},
  volume = {76},
  number = {4},
  pages = {234--243},
  doi = {10.33192/smj.v76i4.267556}
}
Kostenlos starten →